Great write up on PTX. Interesting that Ph2 breast cancer continues to do well - 40% complete response and 60% partial and only one more patient required to have a complete response to expand the Ph2 trial - but no real insights yet to AML. Other interesting point that
“Ptx 200 we might partner, but with PTX-1 00, we could realistically carry that ourselves because we have a fast-track development plan,” he said.
